Less Ads, More Data, More Tools Register for FREE

Pin to quick picksItaconix Plc Regulatory News (ITX)

Share Price Information for Itaconix Plc (ITX)

Share Price is delayed by 15 minutes
Get Live Data
108.50    0.00 (0.00%)
Bid:
107.00
Ask:
110.00
Spread: 3.00 (2.804%)
Market Cap: £14.63m
ITX Live PriceLast checked at - London Stock Exchange

Intraday Itaconix Plc Share Chart

Development of Next Generation Plant-Based Paints

29 May 2026 07:00

RNS Number : 1349G
Itaconix PLC
29 May 2026
 

For release on Reach: 29 May 2026

Itaconix plc

("Itaconix", the "Company" or the "Group")

Itaconix Advances Development of Next Generation Plant-Based Paints

Itaconix plc (AIM: ITX) (OTCQB: ITXXF), a leading innovator in high-performance plant-based specialty polymers used in consumer products, announces further progress in the development of a new class of paints enabled by Itaconix's line of BIO*Asterix® ingredients.

The Company has filed a patent application covering paint formulations incorporating BIO*Asterix® ingredients and has also filed a trademark application relating to the new class of paints under development.

As part of the next stage of development activities, Itaconix has signed an agreement with an established specialty paint company to support the completion and evaluation of initial paint products using BIO*Asterix® ingredients.

The programme forms part of the Company's broader strategy to expand the application of its plant-based polymer platform into new application categories, with a strong focus on product safety, performance, and sustainability.

John R. Shaw, CEO of Itaconix, commented:

"We believe our BIO*Asterix® ingredients can enable a new and differentiated class of paints with compelling safety and sustainability characteristics. Protecting our proprietary space with this class of paints and collaborating with an experienced industry partner are important next steps in developing and assessing our long-term potential in paint and coating applications. While still at an early stage, we are encouraged by the advances we are making and look forward to further evaluating the opportunity over time."

- Ends -

Enquiries:

Itaconix plc +1 603 775 4400

John R. Shaw / Laura Denner

Rosewood +44 (0) 207 653 8704

Financial PR

John West / Llew Angus / Lily Pearce

Canaccord Genuity +44 (0) 7523 8000

Nominated Adviser and Broker

Adam James / Harry Pardoe

 About Itaconix

Itaconix uses its proprietary plant-based polymer technology platform to produce and sell specialty ingredients that improve the safety, performance, and sustainability of consumer products. The Company's current ingredients are enabling and leading new generations of products in detergents, hygiene, and hair care. Itaconix's products contribute to the global low carbon economy.

www.itaconix.com

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAUWOWRNKUVUAR
Date   Source Headline
8th Jul 20267:00 amRNS-RAgreement Extended with Bonals Technologies
10th Jun 20262:43 pmRNSResult of AGM
2nd Jun 20267:00 amRNSMello 2026 Presentation and Update on Trading
1st Jun 20267:00 amRNS-RProgress in Crop Production Field Trials
29th May 20267:00 amRNS-RDevelopment of Next Generation Plant-Based Paints
27th May 20267:00 amRNS-RLaunch of New Marketing Program for Detergents
14th May 20265:55 pmRNSAdjournment of AGM
6th May 20264:46 pmRNSDirector/PDMR Shareholding
27th Apr 20266:16 pmRNSTR-1
23rd Apr 20267:00 amRNSGrants of Options & PDMR dealings
24th Mar 20267:00 amRNSPreliminary Results
28th Jan 20267:00 amRNSTR-1
16th Jan 20265:29 pmRNSDirector/PDMR Shareholding
13th Jan 20267:00 amRNSFull Year Trading Update
15th Sep 20257:00 amRNSHalf Year Results
4th Sep 20257:00 amRNSNotice of Interim Results
27th Aug 20258:19 amRNSTR-1
23rd Jul 20257:00 amRNSH1 2025 Trading Update
16th Jul 20257:00 amRNS-RCroda expands agreement: sustainable odour control
1st Jul 20257:00 amRNS-RCommercial Plant-Based Product Launch
8th May 20252:20 pmRNSResult of AGM
6th May 202512:24 pmRNSTR-1
2nd May 20255:28 pmRNSNotice of AGM
1st May 20257:00 amRNSUpdate on US Tariffs
7th Apr 20257:00 amRNSGrants of Options & PDMR dealings
31st Mar 20257:00 amRNSPreliminary Results
18th Mar 20257:00 amRNSNotice of Results and Company Presentation
22nd Jan 20257:00 amRNSTrading Update
5th Nov 20247:00 amRNSTrading Update
10th Oct 20247:00 amRNSChange of Auditor
10th Sep 20247:00 amRNSHalf Year Results
2nd Sep 20247:00 amRNSNotice of Interim Results, Investor Presentation
16th Jul 20247:00 amRNSH1 2024 Trading Update
20th May 20243:03 pmRNSResult of AGM
20th May 20247:00 amRNSAGM Statement and Trading Update
29th Apr 20247:00 amRNSLaunch of two plant-based performance ingredients
19th Apr 20247:00 amRNSGrants of Options & PDMR dealings
15th Apr 20247:00 amRNSPreliminary Results and Notice of AGM
8th Apr 20247:00 amRNSNotice of Results
2nd Apr 20247:00 amRNSTrading Statement
27th Feb 20247:00 amRNSTrading Update
9th Feb 20247:00 amRNSAppointment of Non-Executive Director
26th Jan 20247:00 amRNSAppointment: Nominated Adviser and Sole Broker
15th Dec 20237:00 amRNSDirector/PDMR Shareholding
15th Dec 20237:00 amRNSDirector/PDMR Shareholding
7th Dec 20237:00 amRNSTrading Update
30th Oct 20237:00 amRNSDirector/PDMR Shareholding
26th Oct 20235:28 pmRNSDirector/PDMR Shareholding
19th Oct 20235:08 pmRNSDirector/PDMR Shareholding
19th Oct 20237:00 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.